Authors
Latest:
AI-based Social Listening as Aid to PharmacovigilanceHow artificial intelligence can help pharma filter out the online noise when monitoring for safety signals on the web.
Latest:
Pharma Companies Can Solve the Social Media Adverse Events Reporting Problem and Stop WorryingOrganizations can now confidently leverage social media and messaging platforms to market and share content, writes Dawn Lacallade.
Latest:
Meaningful Insights with Graph TechnologyEmil Eifrem examines how life science researchers can uncover new insights using the in-built power of graph technology.
Latest:
What's Behind the Clinical Innovation Gap?In terms of important clinical benefits and outcomes, modern biotech products have rarely shown the advantages of older generations of drugs, writes Bagrat Lalayan.
Latest:
Real-World Data Networks: Automating & Reducing the Burden of Clinical Studies and RegistriesMon, Aug 8, 2022 1:00pm EST | 10:00am PST | 7:00pm CEST Real-world data networks are changing how data is collected and leveraged for evidence generation. A tech-enabled platform approach can significantly automate and reduce the burden of clinical study programs and registries, improve site and patient engagement and lower costs.
Latest:
Reinventing the Role of Medical AffairsAs digital technologies transform drug development and marketing, a retooled medical affairs function can be a competitive differentiator.
Latest:
Upward Mobility: Optimizing Your Pharma T-ProfileWith lessons and perspectives from the field, the importance of harnessing the right combination of skills to advance up and across career ladders is explored.
Latest:
Customer Experience: A Buzz Term or a Source of Real Commercial Value?Exploring the importance of a customer experience strategy (CXM) through a case study of a life science tools company.
Latest:
Beyond KOL Marketing: Tapping Digital Opinion InfluencersWith healthcare professionals and patients now collecting much of their information online, there is new opportunity for “digital opinion influencers” to amplify traditional KOL messaging-or create their own.
Latest:
Specialty Pharma and Patient Privacy ProtectionPamela Buffone from Privacy Analytics discusses growth in the specialty pharma sector and making patient data protection a top priority.
Latest:
Compliance in the Pharmaceutical Industry: A Marketer's PerspectiveMulti-channel marketing manager Adi Borovick discusses the implications of compliance for marketers in a world where new technologies being created every day.
Latest:
Deregulation Helps Pharma Companies Pursue Digital Health StrategiesIn the 21st Century Cures Act, Congress excluded from FDA regulation certain clinical decision support, or CDS, software.
Latest:
Launching a New Drug: An Overview of Common MistakesJackie DeAngelis outlines three common mistakes that hinder access attainment when launching a new drug.
Latest:
South Florida Delivers on Pharma-Friendly DistributionThis article discusses the supply chain benefits of pharma companies distributing from South Florida.
Latest:
Harnessing the Value of AI In Customer EngagementBy using correct data and pertinent ML algorithms, customer engagement leaders can identify deep insights into customer behavior and make the right interventions to transform the customer experience.
Latest:
Complicated vs Complex Challenges in PharmaMost challenges boil down to two simple categories: "complicated" and "complex". Knowing how to categorize each problem is key to solving it, writes Steve Figman.
Latest:
The Reluctant Customer: Using Personas to Improve ComplianceConsumers of life sciences products are reluctant customers, and this reluctance can turn into non-compliance. Organizations and providers need to understand patients at a human level, and what will motivate them to stay with a treatment plan, writes John Pagliuca.
Latest:
Could Valeant Pharmaceuticals Have Gifted Teva its "Biggest Commercial Hope"?Intellectual property analysis of one recently approved drug shows how Valiant might have missed out on at least one vital acquisition opportunity. Duncan Clark reports.
Latest:
Ukraine: Protecting Investments through Entry Agreements Between Pharma and GovernmentLana Sinichkina, Kateryna Oliinyk and Yevgeniya Ocheretko discuss how the recent settlement between Gilead and Ukraine's Ministry of Health could promote earlier market access in the country.
